Abstract
Introduction
Analytical Tool - Current & Future Lung Cancer Therapeutics is a premium combo
product of "Current and Future Therapies for Lung Cancer: A Therapeutic &
Competitive Insight" and "Lung Cancer Drug Pipeline Update 2006".
According to market analytical studies, the therapeutic lung cancer drug
market is predicted to exceed $4 billion between 2010 and 2015. Chemotherapy
drugs will experience generic erosion and three major chemotherapy drugs go
off patent before 2012; Aventisï Taxotere (docetaxel), Bristol-Myers
Squibbïs Paraplatin (carboplatin) and Eli Lillyïs Gemzar
(gemcitabine). The third-generation chemotherapeutic agents have expanded the
therapeutic options in the treatment of advanced lung cancer. However, despite
their contributions, science has reached a therapeutic plateau. Indeed, both
Avastin and Efaproxyn have generated exciting data.
This combo product assists in your strategic planning decisions in oncology
drug development. Understand the clinical and strategic challenges towards the
commercialization of drugs in lung cancer treatments. Assess opportunities and
risks for the continued development of innovative developmental treatments.
System Requirements
- - AMD-Athlon/Pentium II PC
- - Windows 98/NT4/2000/ME/XP/VISTA
- - 8x-speed CD Rom drive
- - SVGA 16 bit display. (32 bit recommended)
- - 32 MB of available RAM (128 MB recommended)
- - Internet access (for related internet resources)
| 
View Cart
